Evidence map›Paper›PMID 41672066›Full record

ArticleCell chemical biology2026

Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis.

Peter Geon Kim, Christopher B Hergott, Aidan P Miller, Amy Deik, Meaghan Boileau, Kevin Bullock, Kerry A Pierce, Angelina H Choy, Wesley Shin, Marie McConkey and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Peter Geon KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Center, Mass General Research Institute, Massachusetts General Hospital, Boston, MA, USA.
Christopher B HergottDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Aidan P MillerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amy DeikBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Meaghan BoileauDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kevin BullockBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Kerry A PierceBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Angelina H ChoyBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Wesley ShinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marie McConkeyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Justin LokeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; CRUK Manchester Institute, University of Manchester, Manchester, UK.
Birgitta A RybackDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Michael N TrinhDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Justine C RutterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hong YueDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Hojong YoonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Paul ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shourya S Roy BurmanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Matthew G Vander HeidenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Scott A ArmstrongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Clary ClishBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Benjamin L EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: benjamin_ebert@dfci.harvard.edu.

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
The role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9M
A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer TherapyK99CA287069 · NCI · BROAD INSTITUTE, INC. · PI YOON, HOJONG · 2024 to 2024
$171k
NCI NIH HHS K99 CA287069NCI NIH HHS P01 CA066996NCI NIH HHS R35 CA253125NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Somatic mutations in TET2 drive hyper-inflammation in clonal hematopoiesis of indeterminate potential (CHIP), but the molecular link between TET2 inactivation and myeloid immune activation remains unclear. We used in vivo genome-wide genetic perturbations enabled by ultra-diverse barcoding in primary wild-type (WT) or Tet2 knockout (KO) Cas9

Indexed as

Clonal HematopoiesisDNA-Binding ProteinsImmunity, InnateProto-Oncogene ProteinsAnimalsATP Citrate (pro-S)-LyaseDioxygenasesHematopoiesisHematopoietic Stem CellsHumansInflammationMiceMice, Inbred C57BLMice, KnockoutMutationN-AcetylglucosaminyltransferasesATP Citrate (pro-S)-LyaseDioxygenasesDNA-Binding ProteinsN-AcetylglucosaminyltransferasesOgt protein, mouseProto-Oncogene ProteinsTet2 protein, mouseclonal hematopoiesishematopoietic stem-progenitor screenslipid dropletsTet2-mutant inflammation

Identifiers

PMID41672066
PMCPMC12933725

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.